Amedeo Smart

Free Medical Literature Service

 

Amedeo

Chronic Heart Failure
  Free Subscription

Articles published in
J Mol Cell Cardiol
    March 2024
  1. NGUYEN T, Rosa-Garrido M, Sadek H, Garry DJ, et al
    Promoting cardiomyocyte proliferation for myocardial regeneration in large mammals.
    J Mol Cell Cardiol. 2024;188:52-60.
    >> Share

    February 2024
  2. ANTIPENKO S, Mayfield N, Jinno M, Gunzer M, et al
    Neutrophils are indispensable for adverse cardiac remodeling in heart failure.
    J Mol Cell Cardiol. 2024;189:1-11.
    >> Share

  3. SOMA Y, Tani H, Morita-Umei Y, Kishino Y, et al
    Pluripotent stem cell-based cardiac regenerative therapy for heart failure.
    J Mol Cell Cardiol. 2024;187:90-100.
    >> Share

  4. SAKAMOTO T, Kelly DP
    Cardiac maturation.
    J Mol Cell Cardiol. 2024;187:38-50.
    >> Share

    January 2024
  5. SHI L, Li X, Zhang M, Qin C, et al
    Downregulation of Wtap causes dilated cardiomyopathy and heart failure.
    J Mol Cell Cardiol. 2024 Jan 13:S0022-2828(24)00002.
    >> Share

  6. SHINTANI Y, Fukushima S, Varela-Carver A, Lee J, et al
    Corrigendum to "Donor cell-type specific paracrine effects of cell transplantation for post-infarction heart failure" [J Mol Cell Cardiol 47 (2009) 288-295].
    J Mol Cell Cardiol. 2024 Jan 10:S0022-2828(24)00001.
    >> Share

  7. CHU Y, Hua Y, He L, He J, et al
    beta-hydroxybutyrate administered at reperfusion reduces infarct size and preserves cardiac function by improving mitochondrial function through autophagy in male mice.
    J Mol Cell Cardiol. 2024;186:31-44.
    >> Share

    November 2023
  8. MANGIONE MC, Wen J, Cao DJ
    Mechanistic target of rapamycin in regulating macrophage function in inflammatory cardiovascular diseases.
    J Mol Cell Cardiol. 2023;186:111-124.
    >> Share

  9. CHEN S, Wang K, Wang J, Chen X, et al
    Profiling cardiomyocytes at single cell resolution reveals COX7B could be a potential target for attenuating heart failure in cardiac hypertrophy.
    J Mol Cell Cardiol. 2023;186:45-56.
    >> Share

    October 2023
  10. WADDELL HMM, Mereacre V, Alvarado FJ, Munro ML, et al
    Clustering properties of the cardiac ryanodine receptor in health and heart failure.
    J Mol Cell Cardiol. 2023;185:38-49.
    >> Share

  11. ZHAO C, Jiang X, Peng L, Zhang Y, et al
    Glimepiride, a novel soluble epoxide hydrolase inhibitor, protects against heart failure via increasing epoxyeicosatrienoic acids.
    J Mol Cell Cardiol. 2023;185:13-25.
    >> Share

  12. MENASCHE P
    Human PSC-derived cardiac cells and their products: therapies for cardiac repair.
    J Mol Cell Cardiol. 2023;183:14-21.
    >> Share

    September 2023
  13. LIU Z, Liu Z, Xu X, Zhou Y, et al
    Role of ventrolateral part of ventromedial hypothalamus in post-myocardial infarction cardiac dysfunction induced by sympathetic nervous system.
    J Mol Cell Cardiol. 2023 Sep 30:S0022-2828(23)00154.
    >> Share

  14. PEZHOUMAN A, Nguyen NB, Kay M, Kanjilal B, et al
    Cardiac regeneration - Past advancements, current challenges, and future directions.
    J Mol Cell Cardiol. 2023;182:75-85.
    >> Share

    August 2023
  15. KMIETCZYK V, Oelschlager J, Gupta P, Varma E, et al
    Ythdf2 regulates cardiac remodeling through its mRNA target transcripts.
    J Mol Cell Cardiol. 2023;181:57-66.
    >> Share

    July 2023
  16. KOBAYASHI S, Yamamoto T, Yano M
    RyR2-stabilization therapy with dantrolene against left ventricular remodeling and lethal arrhythmia in heart failure.
    J Mol Cell Cardiol. 2023 Jul 5:S0022-2828(23)00108.
    >> Share

    June 2023
  17. MONTANES-AGUDO P, Pinto YM, Creemers EE
    Splicing factors in the heart: Uncovering shared and unique targets.
    J Mol Cell Cardiol. 2023;179:72-79.
    >> Share

    May 2023
  18. YAMADA Y, Sadahiro T, Ieda M
    Development of direct cardiac reprogramming for clinical applications.
    J Mol Cell Cardiol. 2023;178:1-8.
    >> Share

    April 2023
  19. MEHDIPOUR M, Park S, Huang GN
    Unlocking cardiomyocyte renewal potential for myocardial regeneration therapy.
    J Mol Cell Cardiol. 2023;177:9-20.
    >> Share

  20. LI R, Xiang C, Li Y, Nie Y, et al
    Targeting immunoregulation for cardiac regeneration.
    J Mol Cell Cardiol. 2023;177:1-8.
    >> Share

    March 2023
  21. GARRY GA, Olson EN
    Reprogramming of cardiac cell fate as a therapeutic strategy for ischemic heart disease.
    J Mol Cell Cardiol. 2023 Mar 28:S0022-2828(23)00058.
    >> Share

  22. FUJII S, Kobayashi S, Chang Y, Nawata J, et al
    RyR2-targeting therapy prevents left ventricular remodeling and ventricular tachycardia in post-infarction heart failure.
    J Mol Cell Cardiol. 2023 Mar 22:S0022-2828(23)00052.
    >> Share

    January 2023
  23. ZHANG J, Song Y, Li Y, Lin HB, et al
    Iron homeostasis in the heart: Molecular mechanisms and pharmacological implications.
    J Mol Cell Cardiol. 2023;174:15-24.
    >> Share

  24. KHALILIMEYBODI A, Riaz M, Campbell SG, Omens JH, et al
    Signaling network model of cardiomyocyte morphological changes in familial cardiomyopathy.
    J Mol Cell Cardiol. 2023;174:1-14.
    >> Share

    December 2022
  25. ABOUMSALLEM JP, Shi C, De Wit S, Markousis-Mavrogenis G, et al
    Multi-omics analyses identify molecular signatures with prognostic values in different heart failure aetiologies.
    J Mol Cell Cardiol. 2022;175:13-28.
    >> Share

  26. DELBRIDGE LMD, Bell JR, Weeks KL, Raaijmakers AJA, et al
    HFpEF etiology - Can focus on sex-specific mechanisms deliver insights for all?
    J Mol Cell Cardiol. 2022;173:71-72.
    >> Share

  27. NAH J, Zablocki D, Sadoshima J
    The role of autophagic cell death in cardiac disease.
    J Mol Cell Cardiol. 2022;173:16-24.
    >> Share

    November 2022
  28. GARRY DJ, Weiner JI, Greising SM, Garry MG, et al
    Mechanisms and strategies to promote cardiac xenotransplantation.
    J Mol Cell Cardiol. 2022;172:109-119.
    >> Share

  29. FOWLER ED, Wang N, Hezzell MJ, Chanoit G, et al
    Improved Ca(2+) release synchrony following selective modification of Itof and phase 1 repolarization in normal and failing ventricular myocytes.
    J Mol Cell Cardiol. 2022;172:52-62.
    >> Share

    October 2022
  30. YANG X, Kawasaki NK, Min J, Matsui T, et al
    Ferroptosis in heart failure.
    J Mol Cell Cardiol. 2022 Oct 20. pii: S0022-2828(22)00537.
    >> Share

  31. HUNTER JD, Hancko A, Shakya P, Hill R, et al
    Characterization of decellularized left and right ventricular myocardial matrix hydrogels and their effects on cardiac progenitor cells.
    J Mol Cell Cardiol. 2022;171:45-55.
    >> Share

    September 2022
  32. JOHNSON DM, Pavlovic D
    What is actually preserved in HFpEF? Focus on myocyte calcium handling remodelling.
    J Mol Cell Cardiol. 2022;170:115-116.
    >> Share

  33. ZHU W, Sun J, Bishop SP, Sadek H, et al
    Turning back the clock: A concise viewpoint of cardiomyocyte cell cycle activation for myocardial regeneration and repair.
    J Mol Cell Cardiol. 2022;170:15-21.
    >> Share

    August 2022
  34. FU J, Li L, Chen L, Su C, et al
    PGE2 protects against heart failure through inhibiting TGF-beta1 synthesis in cardiomyocytes and crosstalk between TGF-beta1 and GRK2.
    J Mol Cell Cardiol. 2022;172:63-77.
    >> Share

  35. THARP CA, McKinsey TA
    Tissue is the issue: Endomyocardial biopsies to elucidate molecular mechanisms and tailor therapy for HFpEF.
    J Mol Cell Cardiol. 2022;169:111-112.
    >> Share

  36. GUO X, Chen Y, Liu Q
    Necroptosis in heart disease: Molecular mechanisms and therapeutic implications.
    J Mol Cell Cardiol. 2022;169:74-83.
    >> Share

  37. GHEBLAWI M, de Oliveira AA, Williams VR, John R, et al
    An advanced endothelial murine HFpEF model: eNOS is critical for angiotensin 1-7 rescue of the diabetic phenotype.
    J Mol Cell Cardiol. 2022;169:10-12.
    >> Share

    July 2022
  38. FERRERO KM, Koch WJ
    GRK2 in cardiovascular disease and its potential as a therapeutic target.
    J Mol Cell Cardiol. 2022;172:14-23.
    >> Share

  39. MARTENS P, Nguyen C, Tang WHW
    Is epicardial adipose tissue a key pathophysiologic target in heart failure with preserved ejection?
    J Mol Cell Cardiol. 2022;171:69-70.
    >> Share

  40. BODE D, Sotomayor-Flores C, Schiattarella GG
    Up next: The dawn of systems biology in HFpEF research.
    J Mol Cell Cardiol. 2022;168:96-97.
    >> Share

  41. WITHAAR C, Li S, Meems LMG, Sillje HHW, et al
    Aging and HFpEF: Are we running out of time?
    J Mol Cell Cardiol. 2022;168:33-34.
    >> Share

  42. VALERO-MUNOZ M, Sam F
    A misdirected conundrum in translational HFpEF research.
    J Mol Cell Cardiol. 2022;168:1-2.
    >> Share

    June 2022
  43. WEERTS J, Mourmans SGJ, Eringa E, van Empel VPM, et al
    Improving insights into the heterogeneous HFpEF syndrome through microvascular research.
    J Mol Cell Cardiol. 2022;167:106-108.
    >> Share

  44. EMTER CA
    A 'Swine Time' for HFpEF: Multiple animal models for a myriad of clinical phenotypes.
    J Mol Cell Cardiol. 2022;167:15-16.
    >> Share

    May 2022
  45. CHENG G, Zhu D, Huang K, Caranasos TG, et al
    Minimally invasive delivery of a hydrogel-based exosome patch to prevent heart failure.
    J Mol Cell Cardiol. 2022 May 3. pii: S0022-2828(22)00085.
    >> Share

  46. KANASSATEGA RS, Bunch TA, Lepak VC, Wang C, et al
    Human cardiac myosin-binding protein C phosphorylation- and mutation-dependent structural dynamics monitored by time-resolved FRET.
    J Mol Cell Cardiol. 2022;166:116-126.
    >> Share

  47. ZHAO Y, Godier-Furnemont A, Bax NAM, Bouten CVC, et al
    Changes in extracellular matrix in failing human non-ischemic and ischemic hearts with mechanical unloading.
    J Mol Cell Cardiol. 2022;166:137-151.
    >> Share

    April 2022
  48. SEDEJ S, Abdellatif M
    Metabolic therapy for managing heart failure with preserved ejection fraction.
    J Mol Cell Cardiol. 2022;168:68-69.
    >> Share

  49. MOTURI S, Ghosh-Choudhary SK, Finkel T
    Cardiovascular disease and the biology of aging.
    J Mol Cell Cardiol. 2022;167:109-117.
    >> Share

  50. WANG C, Zhang Y, Methawasin M, Braz CU, et al
    RBM20(S639G) mutation is a high genetic risk factor for premature death through RNA-protein condensates.
    J Mol Cell Cardiol. 2022;165:115-129.
    >> Share

    March 2022
  51. GARBINCIUS JF, Luongo TS, Jadiya P, Hildebrand AN, et al
    Enhanced NCLX-dependent mitochondrial Ca(2+) efflux attenuates pathological remodeling in heart failure.
    J Mol Cell Cardiol. 2022;167:52-66.
    >> Share

  52. ABDELLATIF M, Kroemer G
    Heart failure with preserved ejection fraction: An age-related condition.
    J Mol Cell Cardiol. 2022;167:83-84.
    >> Share

  53. DYCK JRB, Sossalla S, Hamdani N, Coronel R, et al
    Cardiac mechanisms of the beneficial effects of SGLT2 inhibitors in heart failure: Evidence for potential off-target effects.
    J Mol Cell Cardiol. 2022;167:17-31.
    >> Share

  54. WANG YL, Bai L, Shi XR, Zhu H, et al
    Osteoblast MR deficiency protects against adverse ventricular remodeling after myocardial infarction.
    J Mol Cell Cardiol. 2022 Mar 18. pii: S0022-2828(22)00047.
    >> Share

  55. QIU Y, Pan X, Chen Y, Xiao J, et al
    Hallmarks of exercised heart.
    J Mol Cell Cardiol. 2022;164:126-135.
    >> Share

  56. WANG N, Dries E, Fowler ED, Harmer SC, et al
    Inducing Ito,f and phase 1 repolarization of the cardiac action potential with a Kv4.3/KChIP2.1 bicistronic transgene.
    J Mol Cell Cardiol. 2022;164:29-41.
    >> Share

  57. TANI H, Tohyama S, Kishino Y, Kanazawa H, et al
    Production of functional cardiomyocytes and cardiac tissue from human induced pluripotent stem cells for regenerative therapy.
    J Mol Cell Cardiol. 2022;164:83-91.
    >> Share

    February 2022
  58. ESCHENHAGEN T, Ridders K, Weinberger F
    How to repair a broken heart with pluripotent stem cell-derived cardiomyocytes.
    J Mol Cell Cardiol. 2022;163:106-117.
    >> Share

  59. STENZIG J, Lemoine MD, Stoter AMS, Wrona KM, et al
    Recapitulation of dyssynchrony-associated contractile impairment in asymmetrically paced engineered heart tissue.
    J Mol Cell Cardiol. 2022;163:97-105.
    >> Share

    January 2022
  60. LIU X, Zhang Y, Deng Y, Yang L, et al
    Mitochondrial protein hyperacetylation underpins heart failure with preserved ejection fraction in mice.
    J Mol Cell Cardiol. 2022;165:76-85.
    >> Share

    November 2021
  61. CHAPSKI DJ, Cabaj M, Morselli M, Mason RJ, et al
    Early adaptive chromatin remodeling events precede pathologic phenotypes and are reinforced in the failing heart.
    J Mol Cell Cardiol. 2021;160:73-86.
    >> Share

    October 2021
  62. CAGGIANO LR, Holmes JW, Witzenburg CM
    Individual variability in animal-specific hemodynamic compensation following myocardial infarction.
    J Mol Cell Cardiol. 2021 Oct 28. pii: S0022-2828(21)00207.
    >> Share

    September 2021
  63. DAVIS K, Azarcon P, Hickenlooper S, Bia R, et al
    The role of demethylases in cardiac development and disease.
    J Mol Cell Cardiol. 2021;158:89-100.
    >> Share

  64. SHEN S, Sewanan LR, Campbell SG
    Evidence for synergy between sarcomeres and fibroblasts in an in vitro model of myocardial reverse remodeling.
    J Mol Cell Cardiol. 2021;158:11-25.
    >> Share

  65. RITTERHOFF J, McMillen TS, Villet O, Young S, et al
    Increasing fatty acid oxidation elicits a sex-dependent response in failing mouse hearts.
    J Mol Cell Cardiol. 2021;158:1-10.
    >> Share

    August 2021
  66. AKSENTIJEVIC D, Shattock MJ
    With a grain of salt: Sodium elevation and metabolic remodelling in heart failure.
    J Mol Cell Cardiol. 2021 Aug 6. pii: S0022-2828(21)00156.
    >> Share

    July 2021
  67. MASHALI MA, Saad NS, Canan BD, Elnakish MT, et al
    Impact of etiology on force and kinetics of left ventricular end-stage failing human myocardium.
    J Mol Cell Cardiol. 2021;156:7-19.
    >> Share

    June 2021
  68. PATEREK A, Okninska M, Chajduk E, Polkowska-Motrenko H, et al
    Systemic iron deficiency does not affect the cardiac iron content and progression of heart failure.
    J Mol Cell Cardiol. 2021;159:16-27.
    >> Share

  69. GARNIER A, Bork NI, Jacquet E, Zipfel S, et al
    Mapping genetic changes in the cAMP-signaling cascade in human atria.
    J Mol Cell Cardiol. 2021;155:10-20.
    >> Share

    May 2021
  70. YAN J, Killingsworth C, Walcott G, Zhu Y, et al
    Molecular remodeling of Cx43, but not structural remodeling, promotes arrhythmias in an arrhythmogenic canine model of nonischemic heart failure.
    J Mol Cell Cardiol. 2021 May 25. pii: S0022-2828(21)00106.
    >> Share

  71. IGAKI Y, Tanno M, Sato T, Kouzu H, et al
    Xanthine oxidoreductase-mediated injury is amplified by upregulated AMP deaminase in type 2 diabetic rat hearts under the condition of pressure overload.
    J Mol Cell Cardiol. 2021;154:21-31.
    >> Share

  72. MCCABE KJ, Rangamani P
    Computational modeling approaches to cAMP/PKA signaling in cardiomyocytes.
    J Mol Cell Cardiol. 2021;154:32-40.
    >> Share

    February 2021
  73. RATTKA M, Westphal S, Gahr BM, Just S, et al
    Spen deficiency interferes with Connexin 43 expression and leads to heart failure in zebrafish.
    J Mol Cell Cardiol. 2021 Feb 4. pii: S0022-2828(21)00022.
    >> Share

  74. HINGER SA, Wei J, Dorn LE, Whitson BA, et al
    Remodeling of the m(6)A landscape in the heart reveals few conserved post-transcriptional events underlying cardiomyocyte hypertrophy.
    J Mol Cell Cardiol. 2021;151:46-55.
    >> Share

    December 2020
  75. MORA MT, Gong JQX, Sobie EA, Trenor B, et al
    The role of beta-adrenergic system remodeling in human heart failure: A mechanistic investigation.
    J Mol Cell Cardiol. 2020 Dec 13. pii: S0022-2828(20)30344.
    >> Share

  76. MAMIC P, Chaikijurajai T, Tang WHW
    Gut microbiome - A potential mediator of pathogenesis in heart failure and its comorbidities: State-of-the-art review.
    J Mol Cell Cardiol. 2020 Dec 8. pii: S0022-2828(20)30340.
    >> Share

  77. CORTASSA S, Juhaszova M, Aon MA, Zorov DB, et al
    Mitochondrial Ca(2+), redox environment and ROS emission in heart failure: Two sides of the same coin?
    J Mol Cell Cardiol. 2020 Dec 7. pii: S0022-2828(20)30336.
    >> Share

  78. O'ROURKE B, Ashok D, Liu T
    Mitochondrial Ca(2+) in heart failure: Not enough or too much?
    J Mol Cell Cardiol. 2020 Dec 5. pii: S0022-2828(20)30337.
    >> Share

  79. NOMURA S, Komuro I
    Precision medicine for heart failure based on molecular mechanisms The Research Achievement Award Lecture.
    J Mol Cell Cardiol. 2020 Dec 1. pii: S0022-2828(20)30333.
    >> Share

    November 2020
  80. ROLLE IG, Crivellari I, Zanello A, Mazzega E, et al
    Heart failure impairs the mechanotransduction propeties of human cardiac pericytes.
    J Mol Cell Cardiol. 2020;151:15-30.
    >> Share

    March 2020
  81. RAZAVI AC, Bazzano LA, He J, Li S, et al
    Pseudouridine and N-formylmethionine associate with left ventricular mass index: Metabolome-wide association analysis of cardiac remodeling.
    J Mol Cell Cardiol. 2020;140:22-29.
    >> Share

    January 2020
  82. ALI HR, Michel CR, Lin YH, McKinsey TA, et al
    Defining decreased protein succinylation of failing human cardiac myofibrils in ischemic cardiomyopathy.
    J Mol Cell Cardiol. 2020;138:304-317.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016